TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies
Open Access
- 28 February 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 478, 107-121
- https://doi.org/10.1016/j.canlet.2020.02.032
Abstract
No abstract availableKeywords
Funding Information
- Royal College of Surgeons
- Cancer Research UK Liverpool Centre
- University of Liverpool Northwest Cancer Research Centre
- Isle of Man Anti-Cancer Association
- University of Liverpool
This publication has 58 references indexed in Scilit:
- Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational statusCancer, 2011
- Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cellsCancer, 2011
- Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53British Journal of Cancer, 2010
- Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicityProceedings of the National Academy of Sciences of the United States of America, 2010
- Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trialThe Lancet Oncology, 2010
- Genotyping of 73 UM‐SCC head and neck squamous cell carcinoma cell linesHead & Neck, 2009
- Modulation of intracellular ROS levels by TIGAR controls autophagyThe EMBO Journal, 2009
- A catabolic block does not sufficiently explain how 2-deoxy-d-glucose inhibits cell growthProceedings of the National Academy of Sciences of the United States of America, 2008
- TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and NeckThe New England Journal of Medicine, 2007
- Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genesOncogene, 2004